brexucabtagene autoleucel
gilead
['brexu-cel', 'oval study']
postapproval study confirms brexu-cel efficacy, safety in relapsed/refractory b-all #asco23 
Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition